A lawsuit was filed on behalf of investors in Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) shares over alleged securities laws violations. Deadline: January 17, 2017. NASDAQ:ARWR investors should contact the Shareholders Foundation.

San Diego, CA -- (SBWire) -- 11/22/2016 --The Shareholders Foundation announced that an investor, who purchased shares of Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR), filed a lawsuit in California over alleged violations of Federal Securities Laws by Arrowhead Pharmaceuticals Inc.

Investors who purchased shares of Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) have certain options and for certain investors are short and strict deadlines running. Deadline: January 17, 2017. NASDAQ:ARWR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

The plaintiff claims that between May 11, 2015 and November 8, 2016 the defendants made false and/or misleading statements and/or failed to disclose that ARC-520 was fatal at certain doses, that consequently, the U.S. Food & Drug Administration ("FDA") was unlikely to approve ARC-520 as a hepatitis B treatment, that Arrowhead had overstated the approval prospects and commercial viability of ARC-520, and that as a result, Arrowhead's public statements were materially false and misleading at all relevant times.

Pasadena, CA based Arrowhead Pharmaceuticals Inc formerly Arrowhead Research Corporation, is a biopharmaceutical company. Shares of Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) grew from $3.18 per share in February 2016 to as high as $8.08 per share in August 2016.

On November 8, 2016, Arrowhead Pharmaceuticals Inc provided an update on its Heparc-2004 clinical study of ARC-520, its therapeutic candidte under clinical investigation for the treatment of chronic hepatitis B virus (HBV) infection.

Arrowhead Pharmaceuticals Inc said that it was notified verbally by the United States Food & Drug Administration ("FDA") of its decision to place a clinical hold on Heparc-2004. According to the company, the hold stems from deaths at the highest dose of an ongoing non-human primate toxicology study; these deaths are currently under investigation.

Shares of Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) declined from $6.18 per share on November 8, 2016 to as low as $4.09 per share on November 10, 2016.

On November 21, 2016, NASDAQ:ARWR shares closed at $4.35 per share.

Those who purchased shares of Arrowhead Pharmaceuticals Inc have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com